[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"contrast-induced-nephropathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:contrast-induced-nephropathy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,69,110,134,167],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100634958","serum-electrolytes-and-contrast-induced-nephropathy-in-acute-ischemic-stroke-patients-undergoing-endovascular-treatment-100634958",false,"NCT07546448","Serum Electrolytes and Contrast-Induced Nephropathy in Acute Ischemic Stroke Patients Undergoing Endovascular Treatment","The Impact of Serum Electrolyte Levels on the Risk of Contrast-Induced Nephropathy in Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Patients diagnosed with acute ischemic stroke\n* Patients who underwent endovascular therapy for acute ischemic stroke between 2018 and 2026\n* Patients with a baseline NIHSS score of 6 or higher\n* Patients who received iodinated contrast medium during the endovascular procedure\n* Patients managed under general anesthesia\n* Patients with available pre-procedural and post-procedural serum creatinine measurements sufficient to assess contrast-induced acute kidney injury\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Pre-existing acute kidney injury or chronic kidney disease meeting KDIGO stage 1-3 before endovascular therapy\n* APACHE score greater than 25 at the time of the procedure\n* Known allergy or hypersensitivity to iodinated contrast media\n* Exposure to iodinated contrast media within the previous 2 weeks\n* Use of nephrotoxic medications within the previous 2 weeks\n* History of myocardial infarction or previous stroke\n* Use of vasopressor\u002Finotropic agents such as dopamine at the time of the procedure\n* Systemic steroid use at the time of the procedure\n* Incomplete medical records or missing laboratory data required for evaluation of CI-AKI","ALL","18 Years","100 Years",{"count":20,"type":21},250,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate the relationship between serum electrolyte levels and the development of contrast-induced acute kidney injury (CI-AKI) in patients with acute ischemic stroke undergoing endovascular therapy (EVT).\n\nContrast-induced nephropathy remains a significant complication associated with endovascular procedures and is linked to increased morbidity and mortality. While several risk factors have been identified, the role of serum electrolyte imbalances in the development of CI-AKI has not been fully elucidated.\n\nIn this retrospective cohort study, patients treated with EVT between 2018 and 2026 will be analyzed. Patients will be classified based on the presence or absence of CI-AKI according to changes in serum creatinine levels. Demographic data, comorbidities, laboratory parameters-including serum electrolytes-and procedural variables will be compared between groups.\n\nThe primary objective is to determine whether serum electrolyte levels are associated with the risk of CI-AKI. Secondary objectives include evaluating 90-day mortality and dialysis dependency in patients who develop CI-AKI.",[25,26,27],"Acute Ischemic Stroke","Contrast-induced Nephropathy","Acute Kidney Injury",[25,29],"Contrast-Induced Acute Kidney Injury","NOT_YET_RECRUITING","2026-04-16",{"date":33,"type":34},"2026-04-22","ACTUAL",{"date":36,"type":21},"2026-04-20",{"date":38,"type":21},"2026-05-10",{"name":40,"class":41},"Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":42},"100628267","oral-vs-intravenous-hydration-to-prevent-contrast-associated-acute-kidney-injury-in-the-ed-100628267","NCT07459413","Oral vs. Intravenous Hydration to Prevent Contrast-Associated Acute Kidney Injury in the ED","Evaluation of the Effectiveness of Oral Hydration Compared to Intravenous Hydration in Preventing Contrast-Associated Acute Kidney Injury in the Emergency Department : A Randomized Controlled Non-Inferiority Trial","Inclusion Criteria:\n\n* Patients aged 18 years and older.\n* Patients with an estimated Glomerular Filtration Rate (eGFR) between 15-59 mL\u002Fmin\u002F1.73 m².\n* Patients undergoing contrast-enhanced computed tomography (CT) in the emergency department.\n* Patients who have provided written informed consent.\n\nExclusion Criteria:\n\n* Pregnant women.\n* Patients with end-stage renal disease (ESRD) receiving dialysis or those with an eGFR \\\u003C15 mL\u002Fmin\u002F1.73 m².\n* Patients presenting with decompensated heart failure.\n* Patients with a known allergy to iodinated contrast media.\n* Patients with contrast media exposure within the last 72 hours.\n* Patients for whom oral intake is contraindicated or who cannot tolerate oral intake",{"count":51,"type":21},198,"INTERVENTIONAL",[54],"NA","This study is planned to be conducted by emergency physicians between November 7, 2025, and December 7, 2026.\n\nInclusion and Exclusion Criteria The study will include adult patients aged 18 years and older who are considered at risk for Contrast-Associated Acute Kidney Injury (CA-AKI), with an estimated Glomerular Filtration Rate (eGFR) between 15-59 ml\u002Fmin\u002F1.73 m², a clinical indication for contrast-enhanced CT, and who have provided signed informed consent.\n\nExclusion criteria are as follows:\n\nPregnant women.\n\nPatients with a known contrast media allergy.\n\nContrast media exposure within the last 72 hours.\n\nEnd-stage renal disease (ESRD) with eGFR \\\u003C15 ml\u002Fmin\u002F1.73 m² or those receiving dialysis.\n\nPatients with clinical decompensated heart failure.\n\nPatients for whom oral intake is contraindicated or not tolerated.\n\nRandomization and Interventions Prior to randomization, the oral intake capacity of eligible patients will be verified. Participants will be randomized into two groups-IV hydration and oral hydration-at a 1:1 ratio using stratified block randomization based on age and gender.\n\nIV Hydration Group: Isotonic 0.9% NaCl solution will be administered. The regimen consists of 3 ml\u002Fkg for 1 hour pre-procedure, followed by 2 ml\u002Fkg\u002Fhour for 4 hours post-procedure. Patients with an ejection fraction (EF) \\\u003C40% will receive half-doses (1.5 ml\u002Fkg pre-procedure; 1 ml\u002Fkg\u002Fhour for 4 hours post-procedure).\n\nOral Hydration Group: Drinking water will be administered under nursing supervision. The regimen consists of 500 ml 1 hour pre-procedure and 125 ml\u002Fhour for 4 hours post-procedure. Patients with an EF \\\u003C40% will receive half-doses (250 ml pre-procedure; 62.5 ml\u002Fhour post-procedure).\n\nFollow-up and Outcome Measures Baseline renal function tests will be obtained from all patients prior to the protocol. Patients will be re-evaluated for CA-AKI via blood samples taken 48-72 hours after contrast administration.\n\nFurthermore, eGFR changes will be calculated using the Modification of Diet in Renal Disease (MDRD) formula. Mehran Risk Scores will also be determined for each patient. Long-term outcomes, including progression to ESRD (requirement for dialysis) and mortality within 1 month, as well as creatinine levels between days 30-45, will be assessed.",[57,26],"Contrast-Associated Acute Kidney Injury","RECRUITING","2026-03-05",{"date":61,"type":34},"2026-03-09",{"date":63,"type":34},"2025-11-07",{"date":65,"type":21},"2026-12-07",{"name":67,"class":68},"Gaziosmanpasa Research and Education Hospital","OTHER_GOV",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":52,"phases":78,"briefSummary":81,"conditions":82,"keywords":87,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":109},"100437910","phase-2-remote-ischemic-preconditioning-for-renal-and-cardiac-protection-in-congestive-heart-failure-rich-trial-100437910","NCT04982419","Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial","RICH","Inclusion Criteria:\n\n* Age 18 years\n* Diagnosis of heart failure with reduced LVEF \\\u003C50%\n* Pre-procedure intravenous normal saline fluid restriction status\n* Society for Cardiovascular Angiography and Interventions (SCAI) AKI risk score (\\>1%)\n* Referral for coronary angiogram and\u002For PCI\n* Suspected stable coronary artery disease or acute coronary syndrome\n\nExclusion Criteria:\n\n* Inability to give informed consent\n* Unstable BP (SBP \\> 200 or \\\u003C80 mmHg) at the time of enrolment\n* Upper limb peripheral arterial disease\n* Unavailability of at least one arm for RIPC\u002FSham-RIPC application\n* Kidney transplant\n* Renal disease requiring dialysis\n* Prior exposure to contrast media within 72hrs preceding coronary angiography\n* Pregnancy\n* Prisoner",{"count":77,"type":21},240,[79,80],"PHASE2","PHASE3","This is a prospective, double-blind, sham-controlled, multicenter, randomized clinical trial is to study the effects of remote ischemic preconditioning on contrast-associated acute kidney injury, functional capacity, and major adverse kidney events in in patients with congestive heart failure undergoing cardiac catheterization and\u002For percutaneous coronary intervention.",[27,83,84,85,86],"Heart Failure","Contrast Induced Nephropathy","Coronary Angiography","Percutaneous Coronary Intervention",[88,89,90,91,92,93,94,95,96,97,98],"Contrast-induced acute kidney injury","Congestive heart failure","Contrast induced nephropathy","Coronary angiography","Percutaneous coronary intervention","Coronary artery disease","Remote ischemic conditioning","acute coronary syndrome","Acute kidney injury","Major adverse kidney events","Ischemic preconditioning","2025-12-09",{"date":101,"type":34},"2025-12-15",{"date":103,"type":34},"2021-11-01",{"date":105,"type":21},"2029-03-31",{"name":107,"class":108},"VA Office of Research and Development","FED",3,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":117,"sex":16,"minAge":17,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":52,"phases":121,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100615343","early-phase-1-role-of-amlodipine-in-reduction-of-cin-100615343","NCT07291375","Role of Amlodipine in Reduction of CIN","The Effect of Low Dose Oral Amlodipine in Renal Protection From Contrast Induced Nephropathy in Diabetic Patients in Intensive Care Unit","Inclusion Criteria:\n\n* adult patients of both sexes (18:70) diabetic patients with serum creatinine below 1.2 hemodynamically stable patients ASA physical status 2,3\n\nExclusion Criteria:\n\n* patient refusal patients of chronic kidney diseases NPO patients serum creatinine above 1.2 Hypertensive patients",true,"70 Years",{"count":120,"type":21},40,[122],"EARLY_PHASE1","The aim is to assess the benefit of low dose oral amlodipine in renal protection from contrast induced nephropathy in diabetic patients in intensive care unit",[26],"2025-12-05",{"date":127,"type":34},"2025-12-18",{"date":129,"type":21},"2025-12-20",{"date":131,"type":21},"2026-07-01",{"name":133,"class":41},"Minia University",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":52,"phases":144,"briefSummary":145,"conditions":146,"keywords":150,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":42},"100461044","intravenous-vs-oral-hydration-to-reduce-the-risk-of-post-contrast-acute-kidney-injury-after-intravenous-contrast-enhanced-computed-tomography-in-patients-with-severe-chronic-kidney-disease-100461044","NCT05283512","Intravenous vs. Oral Hydration to Reduce the Risk of Post-Contrast Acute Kidney Injury After Intravenous Contrast-Enhanced Computed Tomography in Patients With Severe Chronic Kidney Disease","Intravenous vs. Oral Hydration to Reduce the Risk of Post-Contrast Acute Kidney Injury After Intravenous Contrast-Enhanced Computed Tomography in Patients With Severe Chronic Kidney Disease (ENRICH): A Randomized Controlled Trial","ENRICH","Inclusion Criteria:\n\n* eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n* Scheduled for elective IV CECT\n* Age ≥ 18\n* Signed informed consent\n\nExclusion Criteria:\n\n* Allergy to Iodine\n* Pregnancy\n* Active dialysis treatment\n* Acute infectious or inflammatory disease\n* Acute pre- and\u002For post-renal kidney failure\n* Unable to understand study information",{"count":143,"type":21},254,[54],"The use of contrast media (CM) poses a risk of post-contrast acute kidney injury (PC-AKI), especially among patients chronic kidney disease (CKD). International guidelines recommend intravenous (IV) hydration with isotonic 0.9% NaCl for three-four hours pre-contrast and four-six hours post-contrast. Recent studies have proven that oral hydration or no hydration is non-inferior to IV hydration in patients with mild to moderate CKD (eGFR 30-60 mL\u002Fmin\u002F1.73 m2). However, no randomized controlled trials have evaluated alternative hydration methods against the guideline-recommended hydration protocol for the prevention of PC-AKI in high-risk patients with severe CKD (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2).\n\nThus, the main focus of this trial is to evaluate IV hydration vs. oral hydration for their efficacy to prevent of PC-AKI in patients with severe CKD, who are scheduled for an elective contrast-enhanced CT-scan (CECT) with IV contrast-administration.\n\nOur research hypotheses consist of the following:\n\n1. Oral hydration with bottled tap water is non-inferior to IV-hydration with isotonic 0.9% NaCl as renal prophylaxis to prevent PC-AKI in patients with severe CKD referred for an elective IV CECT.\n2. NGAL and cfDNA are early and precise plasma and urinary biomarkers of PC-AKI with excellent diagnostic and prognostic accuracy for PC-AKI, dialysis, renal adverse events, hospitalization, progression in CKD-symptoms, and all-cause mortality.",[26,147,148,149],"Kidney Injury","Kidney Failure, Chronic","Risk Reduction",[151,152,153,154,155,156,157],"Intravenous","Contrast material","Computed Tomography","Cardiac CT","Prophylaxis","Oral Hydration","IV-hydration","2025-07-29",{"date":160,"type":34},"2025-08-01",{"date":162,"type":34},"2022-04-20",{"date":164,"type":21},"2027-12-31",{"name":166,"class":41},"Odense University Hospital",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":52,"phases":177,"briefSummary":178,"conditions":179,"keywords":181,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":42},"100569529","supplementation-with-beetroot-juice-to-prevent-contrast-associated-nephropathy-during-hospitalization-for-acute-coronary-syndrome-without-st-elevation-100569529","NCT06695429","Supplementation With Beetroot Juice to Prevent Contrast Associated Nephropathy During Hospitalization for Acute Coronary Syndrome Without ST Elevation","Suplementación Con Zumo de REmolacha Para Prevenir la Nefropatía Asociada a Contraste Durante la hospitalización Por Síndrome Coronario Agudo Sin elevación Del ST","RENACS","Inclusion Criteria:\n\n* Diagnosis of Acute Coronary Syndrome without persistent ST segment elevation, with recommendation for invasive management according to the actual Clinical practice guidelines\n* At least moderate or high risk of nephropathy associated with iodinated contrast (Mehran score (without including contrast volume) ≥ 6).\n\nExclusion Criteria:\n\n* \\\u003C18 years old or without capacity to give consent.\n* Refusal to participate in the study.\n* Known hypersensitivity to beetroot or any of its allergens.\n* Pregnant.\n* Inability to take food orally\n* Serious illnesses (not related to ACS or kidney failure), which limits their life expectancy to a period predictably less than 1 year.\n* On dialysis or predialysis at the time of inclusion.\n* ACS with persistent ST segment elevation before inclusion.\n* Shock or inotrope dependence at the time of inclusion\n* PCI already performed before inclusion.\n* Patients receiving intravenous nitroglycerin for \\> 1 hour before inclusion",{"count":176,"type":21},130,[54],"The goal of this study is to compare the possible beneficial effect of beetroot juice supplementation versus the usual management during hospitalization to prevent contrast-induced nephropathy after cardiac catheterizations.\n\nThe study includes patients diagnosed with non-ST elevation acute coronary syndrome with a possible indication for catheterism and high risk of kidney injury related to iodinated contrast.\n\nThe intervention group will drink 500 mL (2 glasses daily, at breakfast and dinner) of beetroot juice added to the usual diet for 7 days or until hospital discharge and will receive the recommendation to maintain a diet rich in inorganic nitrates. The control group will receive the usual diet and recommendations. In both cases, other therapies will be prescribed to prevent contrast-induced nephropathy (hydration and statins) if there is no contraindication.\n\nOur hypothesis is that a compound present in beetroot juice, inorganic nitrates, can prevent the deterioration of kidney function related to contrast due to its vasodilatory effect, in addition to improving the subsequent prognosis of coronary heart disease due to its anti-inflammatory and antiproliferative effects, protector of the endothelium and inhibitor of platelet aggregation. Beetroot juice could also be beneficial in this context due to the antioxidant effect of the betalains it contains.",[180,84],"Non ST Segment Elevation Acute Coronary Syndrome",[182,183,90,184,92,185],"Beetroot juice","Inorganic nitrates","Non ST elevation acute coronary syndrome","Contrast","2025-05-14",{"date":188,"type":34},"2025-05-18",{"date":190,"type":34},"2024-10-07",{"date":192,"type":21},"2027-09-30",{"name":194,"class":41},"Hospital General Universitario Santa Lucia"]